Valacyclovir reduces HIV-1 levels – even when patients do not have herpes – results from a recent study indicate. The result not only means that Valacyclovir can be used effectively with a broader range of HIV-1 patients, but also suggests promising new avenues for the development of HIV-fighting drugs. This insight is particularly significant given that some forms of HIV-1 have become resistant to existing medications.
Science Daily reports that the finding rebuts earlier scientific assumptions that Valacyclovir (brand name, Valtrex) required the presence of the other infection to benefit patients with HIV-1. "These results demonstrated that the mechanism by which Valacyclovir acts against HIV is not only through the presence of HSV-2," said senior author Dr Benigno Rodriguez, associate professor of medicine and infectious diseases, Case Western Reserve University (CWRU) School of Medicine, co-principal investigator, Case Western Reserve University/University Hospitals Case Medical Centre Aids Clinical Trials Unit, and infectious disease specialist with UH Case Medical Centre. Even better, Rodriguez said, studies by these groups helped illuminate exactly how the medication decreases HIV-1 levels. Valacyclovir is activated in virus-infected cells, and then blocks the ability of HIV to reproduce.
HIV-1 can lead to the immune deficiency known as Aids – the herpes simplex virus 2 (HSV-2) causes periodic recurrence of genital herpes lesions, which increase the likelihood that a herpes sufferer may contract HIV through intimate contact. HSV-2 outbreaks are treated with either Acyclovir or the newer generation Valacyclovir, which requires less frequent dosing.
Scientists previously thought that Valacyclovir helped reduce HIV levels and worked by decreasing the immune activation caused by HSV-2. With fewer immune cells to attack, the theory went, HIV-1 could not spread as widely. Yet Dr Leonid Margolis, of the National Institutes of Health (NIH), believed another explanation might exist. After conducting laboratory studies with Acyclovir, an earlier sibling drug of Valacyclovir, Margolis saw that the medication clearly blocked HIV-1 reproduction, even when HSV-2 was absent. Those results helped spur clinical trials of Valacyclovir in people.
Beginning in June, 2009, patients from UH Case Medical Centre and from IMPACTA, the Civic Association for Health and Education in Lima, Peru, started participating in the trials, which lasted until July, 2012. Under its protocols, half the patients took Valacyclovir twice daily for 12 weeks, while the other half took a placebo for the same period of time. After a two-week break from any medications, the two groups switched: those previously on placebo got 12 weeks of the Valacyclovir, and those who already had taken the medication now received placebos. When study participants took Valacyclovir, their HIV viral loads went down, and when they took the placebo, their HIV viral loads went up. Ultimately, a total of 18 patients participated.
"Our most recent clinical study demonstrates that acyclovir blocks HIV replication directly. The anti-HIV activity of valacyclovir does not depend on blocking the inflammation caused by herpes simplex virus 2," said Dr Michael M Lederman, also a senior author. He is the Scott R Inkley professor of medicine, CWRU School of Medicine, and principal investigator of the Case Western Reserve University/University Hospitals Case Medical Centre Aids Clinical Trials Unit and infectious disease specialist with UH Case Medical Centre.
Lederman and Rodriguez believe that the data from this study can inform new drug development. Essentially, researchers would try to design agents based on the Valacyclovir's molecular structure – now proven to block HIV activity.
Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine. For nearly three decades, immunologists' efforts to develop a herpes vaccine have centred on exploiting a single protein found on the virus's outer surface that is known to elicit robust production of antibodies.
Breaking from this approach, Howard Hughes Medical Institute (HHMI) scientists at Albert Einstein College of Medicine have created a genetic mutant lacking that protein. The result is a powerfully effective vaccine against herpes viruses. "We have a very promising new candidate for herpes," says William Jacobs, an HHMI investigator at the Albert Einstein College of Medicine, "but this might also be a good candidate as a vaccine vector for other mucosal diseases, particularly HIV and tuberculosis."
The new vaccine was found to be effective against the two most common forms of herpes that cause cold sores (HSV-1) and genital ulcers (HSV-2). Both are known to infect the body's nerve cells, where the virus can lay dormant for years before symptoms reappear. The new vaccine is the first to prevent this type of latent infection. "With herpes sores you continually get them," Jacobs says. "If our vaccine works in humans as it does in mice, administering it early in life could completely eliminate herpes latency."
HSV-2 is a lifelong, incurable infection that causes recurrent and painful genital sores and increases susceptibility to HIV. Also, babies born to mothers with active genital herpes have a more than 80% mortality rate. Current estimates suggest that 500m people worldwide are infected with HSV-2, with approximately 20m new cases occurring annually. While infection rates in the US hover around 15% to 20%, HSV-2 is highly prevalent in sub-Saharan Africa, where nearly three in four women have contracted the virus, contributing significantly to the region's HIV epidemic. The related virus, HSV-1 is primarily associated with oral lesions, but is a major cause of corneal blindness and infects around 60% of the world's population. Notably, HSV-1 has been increasingly recognized as a cause of genital herpes in the US and other developed countries.
Most prior attempts to construct a herpes vaccine have focused on a glycoprotein called gD that is embedded in the virus's outer envelope. This protein is required for the microbe to enter into and out of cells and to spread from cell-to-cell gD also elicits a vigorous antibody response that many in the field believe is necessary to produce immunity. However, no gD-based vaccine has proven effective. "It was necessary to shake the field up and go another route," says Betsy Herold, a virologist and infectious disease physician at the Albert Einstein College of Medicine and co-study leader of the new research.
As part of a separate ongoing study of the signalling pathway that the herpes virus uses to enter cells, Herold asked Jacobs's lab to engineer a mutant with gD deleted. Though it was not necessarily obvious beforehand, "once we had this mutant in our hands," Herold says, "it was a logical, scientifically driven hypothesis to say, 'This strain would be 100% safe and might elicit a very different immune response than the gD subunit vaccines that have been tried.'" The hypothesis followed from the increasing understanding that, in addition to its critical role in viral entry, gD also has the ability to change the host immune response.
In order to test the gD deletion virus as a vaccine, the researchers grew the virus in a cell line that expresses the HSV-1 version of gD. The HSV-2 virus, with gD deleted from its genome, grabbed the available HSV-1 gD proteins from the cell. When introduced to a mouse, HSV-2 was able to use the HSV-1 gD to enter the mouse's cells. Once inside, HSV-2 replicated abundantly, but because it could not produce gD, future progeny were unable to infect new cells. According to Herold, infected cells then became "little factories for making viral proteins" that spurred the immune system to produce antibodies to HSV-2.
The vaccine completely immunised two common strains of lab mice against HSV-2 when challenged with virus intra-vaginally or on the skin. In fact, no virus could be detected in vaginal washes four days post-challenge and even more importantly, no virus could be found in the nerve tissue, the site where HSV often hides in a latent form only to emerge later to cause disease. Protection against HSV-1, which shares considerable homology with HSV-2, was also demonstrated in both models. The vaccine produced no adverse health effects in a strain of mice with severely compromised immune systems, reflecting the vaccine's overall safety.
Blood serum passively transferred from immunised mice was found to protect wild-type mice, providing a powerful demonstration of the vaccine's efficacy. "No one has ever shown for a skin disease that you can protect against infection with passive transfer," Jacobs says.
Another of the vaccine's surprises is how it works. Many vaccines provoke the production of so-called neutralizing antibodies that directly bind and inactivate virus particles. The new vaccine, however, induces antibody-dependent cell-mediated cytotoxicity (ADCC) in which antibodies attach to a virus and flag it for destruction by immune system sentinels such as white blood cells. Further evidence that the vaccine triggers ADCC comes from the observation that they lost protection when the immune serum was transferred into mice in which the
FcϒR, a protein known to facilitate ADCC, is knocked out.
As to why vaccines based on gD never worked, the team thinks that gD, which elicits a strong neutralizing immune response, may have actually been overwhelming the immune system to the extent that the immune system did not see other component of the virus or gD interfered with the ability evoke ADCC. "Herpes is a pretty smart little virus," Herold says. "It has multiple immune evasion strategies and this is one of many." With gD knocked out, the immune system was able to react effectively to the virus's less dominant components.
The successful implementation of a vaccine based on ADCC could have profound implications for other infections. "It's possible we could clone into this HSV vector pieces of other viruses, such as HIV, and maybe the immune system would produce the same types of ADCC antibodies for those viruses," Herold says.
The robust response generated by the vaccine, as well as its novel mechanism, has the researchers undertaking additional experiments in mice to determine whether it can be used to treat individuals already infected by HSV-1 and HSV-2. The next step for the researchers in producing a herpes vaccine for use in humans is demonstrating its efficacy and safety in an FDA-approved cell line. The researchers are also looking for an industry partner to help make large quantities of the vaccine for future clinical tests.
[link url="http://www.sciencedaily.com/releases/2015/03/150313130741.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed:+sciencedaily/top_news/top_health+(ScienceDaily:+Top+Health+News)"]Full Science Daily report[/link]
[link url="http://cid.oxfordjournals.org/content/early/2015/03/03/cid.civ172"]Clinical Infectious Diseases abstract[/link]
[link url="http://www.hhmi.org/news/radical-vaccine-design-effective-against-herpes-viruses"]Howard Hughes Medical Institute material[/link]
[link url="http://elifesciences.org/content/4/e06883"]eLife article summary[/link]